Abercrombie & Fitch Co. vs AstraZeneca plc — how do they compare? Abercrombie & Fitch Co. trades at $113.91 (market cap $5.24B), while AstraZeneca plc trades at $157.93 (market cap $248.14B). The key difference: AstraZeneca plc is far larger — about 47.4× Abercrombie & Fitch Co.'s market cap, and AstraZeneca plc pays a 2.01% dividend while Abercrombie & Fitch Co. pays none. Which is the better fit depends on your goals.
| ANF | AZN | |
|---|---|---|
Market Cap | $5.24B | $248.14B |
Sector | Consumer Cyclical | Health |
52-Week High | $129.85 | $209.48 |
52-Week Low | $65.61 | $147.06 |
Enterprise Value | $5.91B | $275.41B |
Dividend Yield | — | 2.01% |
Signals from Pluang's Aura AI — not financial advice
ANF trades at $114.45, down 3.44% over 24 hours, with a bullish technical signal from moving averages but bearish oscillators. The stock shows strong fundamentals with a P/E of 11.41, net income margin of 9.34%, and three consecutive quarterly EPS beats. Revenue grew to $4.95 billion in 2025, up from $4.3 billion in 2024, while operating cash flow reached $710.38 million. Recent news highlights institutional buying and an upcoming Q2 2026 earnings report on August 26, 2026.
Outlook is mixed: valuation metrics appear attractive, and earnings momentum supports upside, but overbought RSI levels and competitive retail headwinds pose risks. Analyst consensus is a $112.86 price target with 35.71% buy ratings, suggesting cautious optimism amid near-term volatility.
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
Trailing returns across standard periods
Latest headlines on both assets
Abercrombie & Fitch Co is a specialty retailer that sells casual clothing, personal-care products, and accessories for men, women, and children. It sells direct to consumer through its stores and websites, which include the Abercrombie & Fitch, Abercrombie kids, and Hollister brands. Most stores are in the United States, but the company does have many stores in Canada, Europe, and Asia. All stores are leased. Abercrombie ships to well over 100 countries via its websites. The company sources its merchandise from dozens of vendors that are primarily located in Asia and Central America. Abercrombie has two distribution centers in Ohio to support its North American operations. It uses third-party distributors for sales in Europe and Asia.
Read more on ANF →A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →